The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Self-citationMolecular Targets for Antiepileptic Drug Development
Meldrum, B. S., & Rogawski, M. A. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.11.010 · Cited by 468
SV2, a Brain Synaptic Vesicle Protein Homologous to Bacterial Transporters
Bajjalieh, S. M., Peterson, K., Shinghal, R., & Scheller, R. H. (1992) · Science · doi:10.1126/science.1519064 · Cited by 256
Noyer, M., Gillard, M., Matagne, A., Hénichart, J.-P., & Wülfert, E. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00436-o · Cited by 255
Self-citationKenda, B. M., Matagne, A. C., Talaga, P. E., Pasau, P. M., Differding, E., Lallemand, B. I., Frycia, A. M., Moureau, F. G., Klitgaard, H. V., Gillard, M. R., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030913e · Cited by 226
Self-citationMatagne, A., Margineanu, D., Kenda, B., Michel, P., & Klitgaard, H. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.198 · Cited by 224
Self-citationMolinoff, P. B., Wolfe, B. B., & Weiland, G. A. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90208-3 · Cited by 194
Kaminski, R. M., Matagne, A., Leclercq, K., Gillard, M., Michel, P., Kenda, B., Talaga, P., & Klitgaard, H. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.11.021 · Cited by 169
Self-citationAdjunctive brivaracetam for refractory partial-onset seizures: A randomized, controlled trial
French, J. A., Costantini, C., Brodsky, A., & von Rosenstiel, P. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ec7f7f · Cited by 158
Gillard, M., Chatelain, P., & Fuks, B. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.022 · Cited by 148
Self-citationSargentini‐Maier, M. L., Rolan, P. E., Connell, J., Tytgat, D., Jacobs, T. G., Pigeolet, E., Riethuisen, J., & Stockis, A. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02829.x · Cited by 140
Initial Management of Epilepsy
French, J. A., & Pedley, T. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0801738 · Cited by 129
Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects
Sargentini‐Maier, M. L., Espié, P., Coquette, A., & Stockis, A. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017129 · Cited by 118
Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model
Trenité, D. G. A. K.-N., Genton, P., Parain, D., Masnou, P., Steinhoff, B. J., Jacobs, T., Pigeolet, E., Stockis, A., & Hirsch, É. (2007) · Neurology · doi:10.1212/01.wnl.0000271385.85302.55 · Cited by 109
Benefit of combination therapy in epilepsy: A review of the preclinical evidence with levetiracetam
Kaminski, R. M., Matagne, A., Patsalos, P. N., & Klitgaard, H. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01713.x · Cited by 103
Self-citationConformational Change in an MFS Protein: MD Simulations of LacY
Holyoake, J., & Sansom, M. S. P. (2007) · Structure · doi:10.1016/j.str.2007.06.004 · Cited by 76
Brivaracetam (ucb 34714) inhibits Na+ current in rat cortical neurons in culture
Zona, C., Pieri, M., Carunchio, I., Curcio, L., Klitgaard, H., & Margineanu, D. G. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.09.024 · Cited by 70
Levetiracetam: the first SV2A ligand for the treatment of epilepsy
Klitgaard, H., & Verdru, P. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.11.1537 · Cited by 68
Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain
Gillard, M. R., Fuks, B., Michel, P., Vertongen, P., Massingham, R., & Chatelain, P. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.032 · Cited by 61
Self-citationVisualization of SV2A conformations in situ by the use of Protein Tomography
Lynch, B. A., Matagne, A., Brännström, A., von Euler, A., Jansson, M., Hauzenberger, E., & Söderhäll, J. A. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.145 · Cited by 33
Self-citationBrivaracetam: a new drug in development for epilepsy and neuropathic pain
Malawska, B., & Kulig, K. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.3.361 · Cited by 32
Cited by
Epileptic activity in Alzheimer’s disease: Causes and clinical relevance
Vossel, K. A., Tartaglia, M. C., Nygaard, H. B., Zeman, A. Z., & Miller, B. L. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30044-3 · Cited by 590
Imaging synaptic density in the living human brain
Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6667 · Cited by 575
Mechanisms of action of currently used antiseizure drugs
Sills, G. J., & Rogawski, M. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107966 · Cited by 489
Biton, V., Berkovic, S. F., Abou‐Khalil, B., Sperling, M. R., Johnson, M. E., & Lu, S. (2014) · Epilepsia · doi:10.1111/epi.12433 · Cited by 253
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2013) · Epilepsy Research · doi:10.1016/j.eplepsyres.2012.10.001 · Cited by 243
Metadata
- Authors
- Gillard, M., Fuks, B., Leclercq, K., & Matagne, A.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 664
- Issue
- 1-3
- Pages
- 36-44
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2095271866
- Cited by
- 253
- References
- 22
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.